BLU Share Price Performance
CA$0
0.00 (0.00%)
Price CA$0
Share Pricen/a
BELLUS Health Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
BLU Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
BELLUS Health Inc. Key Details
Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
- -0.68
- 100.00%
- -578,586.67%
- 0%
About BLU
- Founded
- 1993
- Employees
- 74
- CEO
- WebsiteView website
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
